Researchers explore the concept of biologic resectability in defining patient selection for metastasectomy in oligometastatic pancreatic ductal adenocarcinoma (PDAC). They assess safety and oncologic outcomes of metastasectomy in liver, peritoneum, and lung, and evaluate biomarkers like radiographic findings, biochemical markers (CA 19-9, CEA), and inflammatory markers. The study emphasizes the importance of considering biologic, rather than technical, resectability in guiding surgical interventions for PDAC patients with oligometastatic disease.
Review by Koti S, Demyan L, Deutsch G and Weiss M in Ann Surg Oncol
© 2024. The Author(s).